- Home
- HSPO vs NSPR Comparison
HSPO vs NSPR Comparison
Compare HSPO & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSPO
- NSPR
- Stock Information
- Founded
- HSPO 2014
- NSPR 2005
- Country
- HSPO United States
- NSPR Israel
- Employees
- HSPO N/A
- NSPR N/A
- Industry
- HSPO Blank Checks
- NSPR Medical/Dental Instruments
- Sector
- HSPO Finance
- NSPR Health Care
- Exchange
- HSPO Nasdaq
- NSPR Nasdaq
- Market Cap
- HSPO 92.0M
- NSPR 75.6M
- IPO Year
- HSPO 2022
- NSPR N/A
- Fundamental
- Price
- HSPO $11.80
- NSPR $2.65
- Analyst Decision
- HSPO
- NSPR Strong Buy
- Analyst Count
- HSPO 0
- NSPR 2
- Target Price
- HSPO N/A
- NSPR $4.75
- AVG Volume (30 Days)
- HSPO 1.4K
- NSPR 67.4K
- Earning Date
- HSPO 01-01-0001
- NSPR 03-12-2025
- Dividend Yield
- HSPO N/A
- NSPR N/A
- EPS Growth
- HSPO 2.63
- NSPR N/A
- EPS
- HSPO 0.91
- NSPR N/A
- Revenue
- HSPO N/A
- NSPR $7,009,000.00
- Revenue This Year
- HSPO N/A
- NSPR $50.18
- Revenue Next Year
- HSPO N/A
- NSPR $159.56
- P/E Ratio
- HSPO $12.82
- NSPR N/A
- Revenue Growth
- HSPO N/A
- NSPR 12.96
- 52 Week Low
- HSPO $10.87
- NSPR $1.81
- 52 Week High
- HSPO $12.41
- NSPR $3.80
- Technical
- Relative Strength Index (RSI)
- HSPO 52.89
- NSPR 35.10
- Support Level
- HSPO $11.61
- NSPR $2.57
- Resistance Level
- HSPO $11.75
- NSPR $2.78
- Average True Range (ATR)
- HSPO 0.00
- NSPR 0.20
- MACD
- HSPO 0.00
- NSPR -0.02
- Stochastic Oscillator
- HSPO 50.00
- NSPR 6.33
About HSPO Horizon Space Acquisition I Corp.
Horizon Space Acquisition I Corp is a blank check company.
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.